Merck (MRK) announced Monday that it would acquire Tilos Therapeutics for up to $770 million, a potentially massive windfall for a 3-year-old company and a sign of the industry’s hopes for a class of drugs that could be a boon for immunotherapies.

The acquisition is Merck’s third cancer-related purchase in 2019; it also spent more than $1 billion to acquire Peloton Therapeutics in May and $300 million to acquire Immune Design, a publicly traded California immunotherapy company, in February.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy